Related Experiment Video
Updated: Jan 19, 2026
Endocarditis II: Clinical Features of Infective Endocarditis
Published on: June 19, 2025
The Effect of Preexisting Anticoagulation on Cerebrovascular Events in Left-Sided Infective Endocarditis
Kyle A Davis1, Glen Huang2, S Allan Petty2
1Department of Pharmacy, Wake Forest Baptist Medical Center, Winston-Salem, NC.
Insights
Anticoagulation did not significantly alter stroke or bleeding risk in patients with left-sided infective endocarditis. Continuation of anticoagulation is reasonable for patients with existing indications, provided no contraindications exist.
Area of Science:
- Cardiology
- Neurology
- Infectious Diseases
Background:
- Stroke is a common complication of infective endocarditis, particularly left-sided valve infections.
- The role of anticoagulation in managing left-sided infective endocarditis remains controversial regarding stroke and bleeding risks.
Purpose of the Study:
- To assess the impact of anticoagulation on stroke occurrence and bleeding complications in patients with left-sided infective endocarditis.
Main Methods:
- A retrospective study identified 258 patients with left-sided infective endocarditis admitted between December 2011 and April 2018.
- Patients were stratified based on whether they received therapeutic anticoagulation prior to admission.
- The primary outcome was radiographically confirmed stroke at 10 weeks.
Main Results:
- No significant difference in stroke, cerebrovascular hemorrhage, or mortality rates at 10 weeks was observed between anticoagulated and non-anticoagulated groups.
- Patients on anticoagulation were older, more likely to have atrial fibrillation and prosthetic valves, and less likely to have mitral valve involvement.
Conclusions:
- Preexisting anticoagulation did not appear to affect stroke, bleeding, or mortality outcomes at 10 weeks in this patient cohort.
- Continuation of anticoagulation for left-sided infective endocarditis is advisable for patients with a preexisting indication, barring contraindications.
Background:
Stroke is a frequent complication of infective endocarditis, especially infection involving left-sided valves. Management of anticoagulation in left-sided infective endocarditis is controversial as it is unclear whether anticoagulation impacts stroke and bleeding risk in patients with this condition. The objective of this study was to evaluate the effect of anticoagulation on stroke occurrence and bleeding complications in patients with left-sided infective endocarditis.
Methods:
Patients admitted to a tertiary academic hospital with left-sided infective endocarditis between December 2011 and April 2018 were identified. Patients were stratified based on receipt of therapeutic anticoagulation prior to admission. The primary outcome measure was the rate of radiographically confirmed stroke at 10 weeks.
Results:
Two-hundred and fifty-eight consecutive patients with left-sided infective endocarditis were identified. Patients receiving anticoagulation (n = 50) were older (median age 63 vs 52; P = .02), were more likely to have a history of atrial fibrillation (22% vs 8.2%; P < .01), more often had prosthetic valves (38% vs 13.9%; P < .01), and had a lower incidence of mitral valve involvement (40% vs 62%; P < .01), compared with patients not receiving anticoagulation. There was no significant difference in the rate of stroke, cerebrovascular hemorrhage, or mortality at 10 weeks between the two cohorts.
Conclusions:
Preexisting anticoagulation did not appear to have an effect on stroke, cerebrovascular hemorrhage, or mortality in patients with left-sided infective endocarditis at 10 weeks. Continuation of anticoagulation in patients with a definitive preexisting indication should be considered in patients with left-sided infective endocarditis in the absence of other contraindications.
Related Concept Videos
Endocarditis II: Clinical Features of Infective Endocarditis
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
07:30Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Endocarditis I: Introduction
08:00Imaging and 3D Reconstruction of Cerebrovascular Structures in Embryonic Zebrafish
07:08Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

